Anesthetic and Antiemetic Infusion Pumps
Customize your policy alerts
Sign up for Aetna Policy 0607 alerts
Get alerted when Policy 0607 changes without checking for updates manually.
Monitor payer policy activity
This policy discusses clinical evidence, safety concerns, and outcomes related to continuous local anesthetic infusion pumps (including intra-articular, intra-lesional, wound, and catheter-based peripheral nerve infusion systems) for postoperative analgesia across multiple surgical indications. The excerpt covers multiple randomized trials, systematic reviews, safety signals (notably chondrolysis), and comparative effectiveness findings.
No material clinical/coverage changes
Coverage Summary
This policy addresses continuous local anesthetic and anti-emetic infusion pumps (including intra-articular, intra-lesional, wound, and peripheral nerve catheter systems) and summarizes clinical trial evidence and safety findings across multiple surgical indications. Evidence from randomized trials and systematic reviews is heterogeneous and inconsistent: some small RCTs show transient or limited reductions in pain or opioid use, but many studies report no sustained clinically meaningful benefit. Important safety signals—most notably reports of post-arthroscopic glenohumeral and knee chondrolysis associated with continuous intra-articular local anesthetic infusions—have been identified, along with device-related problems (pump malfunction causing toxic serum local anesthetic levels) and infection concerns.
Policy number: 0607. Effective date: 2002-04-23. Last review: 2023-08-31. Next review: 2024-06-27.
Medical Necessity — Evidence Synthesis and Criteria
Evidence synthesis and safety considerations (background)
Summary of clinical trial and safety findings informing coverage decisions:
ANY of the following
- Inconsistent effectiveness: Multiple randomized controlled trials show inconsistent efficacy of continuous local anesthetic infusion pumps compared with saline or standard analgesia across indications (TKA, THA, ICBG sites, abdominal, breast augmentation, rotator cuff, shoulder procedures, abdominoplasty, colorectal surgery). Many studies report no significant improvement in pain scores, opioid consumption, length of stay, or functional outcomes.
Supported by multiple RCTs and systematic reviews noting heterogeneity and small trials
- Transient/limited benefits: Some trials reported modest or transient reductions in pain or opioid use at early time points (e.g., 0–2 hrs or first 24–48 hrs) but no sustained clinically significant benefit.
Early timepoint benefits reported in some RCTs but not sustained
- Mixed donor-site results: Certain smaller trials demonstrated benefit at specific donor sites (e.g., Singh et al. 2005 found reduced narcotic use and pain at iliac crest bone graft harvest site), but other trials contradicted these findings (e.g., Morgan et al. 2006; Puri et al. 2000).
Conflicting RCT evidence for ICBG donor-site analgesia
- Systematic review limitations: Systematic reviews note heterogeneity, small sample sizes, and inability to draw definitive conclusions about effectiveness, optimal catheter placement, dosage, or cost-effectiveness.
Meta-analyses and evidence reviews cite low-quality and heterogeneous data
- Chondrolysis and joint toxicity (safety): Evidence documents significant safety concerns: reports of post-arthroscopic glenohumeral and knee chondrolysis associated with intra-articular infusions of various local anesthetics (bupivacaine, lidocaine, others); FDA review of 35 reports and required label updates; cohort and case series showing associations and dose-dependent signals (higher risk with 0.5% vs 0.25%).
FDA safety communication and multiple case series/retrospective cohorts report chondrolysis
- Device malfunction and systemic toxicity: Case reports and cohort studies noted infections and rare toxic serum levels related to elastomeric pump malfunction (e.g., Baulig et al. 2011 early termination for toxic ropivacaine levels); catheter maintenance may increase infection risk.
Pump malfunction produced toxic serum ropivacaine in trial leading to early termination
- CPNB—potential benefits with ultrasound guidance: Continuous peripheral nerve block catheters (CPNB) evidence suggests benefits when ultrasound-guided placement is used for certain indications (improved analgesia, decreased opioid use, potential reduction in chronic post-surgical pain), with relatively few major complications in large prospective studies; however, RCTs showing shortened hospitalization are few and specific indications need further study.
CPNB literature shows advantages particularly with US-guided techniques
Provider Actions and Prior Authorization
Prior authorization may be required for continuous intra‑articular analgesic infusion
Use of continuous intra-articular analgesic infusion may require prior authorization before initiation. Prior authorization helps ensure appropriate patient selection and documentation given safety concerns.
- Prior authorization may be required for intra-articular continuous local anesthetic infusion.
- Be aware of reported cases of chondrolysis associated with continuous intra-articular infusions; weigh risks vs benefits prior to approval.
Document chondrolysis risk and informed consent
Document that the treating clinician discussed the risk of chondrolysis with the patient and documented a risk/benefit discussion in the medical record prior to using intra‑articular continuous local anesthetic infusion.
- Include details of alternatives considered and rationale for choosing intra‑articular infusion.
- Record expected duration of infusion and planned follow‑up assessments in the chart.
Monitor for device malfunction and systemic/local toxicity
Monitor patients for infusion‑device malfunction and signs of local or systemic toxicity during and after infusion. Reported toxic serum ropivacaine with continuous infusion highlights the need for vigilance.
- Perform regular site checks for signs of infection or catheter malfunction.
- Monitor for neurologic signs, cardiac symptoms, and systemic toxicity; obtain serum drug levels when clinically indicated.
- Document monitoring frequency and any device-related problems in the medical record.
Limit experimental/limited therapies to intractable cases and research settings
Experimental or limited-use infusion therapies (including indications listed in policy) should be used cautiously and generally limited to patients with intractable symptoms who have exhausted standard therapies; prospective randomized controlled trials are needed to establish safety and efficacy.
- Limit experimental uses to cases where conventional therapies have failed and risks are understood and documented.
- Consider referral to clinical trials or centers participating in research whenever available.
Outpatient elastomeric IV antibiotic therapy: confirm stability and ensure clinical monitoring
For outpatient parenteral antibiotic therapy (OPAT) using elastomeric pumps, ensure appropriate molecule stability considerations and structured clinical monitoring to reduce risk of failure or adverse events.
- Confirm the antibiotic molecule is stable in the elastomeric pump for the intended infusion period (dosing interval, temperature, diluent).
- Establish a monitoring plan: vital signs, infusion site checks, laboratory monitoring (e.g., renal function, therapeutic drug monitoring when relevant), and a mechanism for patients to report device failure or adverse effects.
- Provide clear patient/caregiver education on pump operation, storage, and signs that warrant immediate contact.
- Document stability verification and the outpatient monitoring plan in the medical record.
Risk reminder: intra‑articular continuous local anesthetic infusion
When considering intra‑articular continuous local anesthetic infusions, remember the FDA safety communication (2010) regarding risk of postarthroscopic glenohumeral chondrolysis — incorporate that guidance into pre‑procedure counseling and planning.
- Brief reminder: avoid or carefully justify intra‑articular continuous infusions in shoulder arthroscopy patients given chondrolysis reports.
HAIP for intrahepatic cholangiocarcinoma: trial or experienced‑center restriction
Hepatic arterial infusion pumps for intrahepatic cholangiocarcinoma should be limited to clinical trials or performed at experienced centers, consistent with NCCN recommendations and the experimental classification in this policy.
- Restrict hepatic arterial infusion pump chemotherapy (HAIP) to trial settings or specialized centers with established expertise.
Background and Key Evidence
Randomized trials and systematic reviews report inconsistent efficacy of continuous local anesthetic infusion pumps: several well-designed RCTs found only modest, short-lived improvements (for example, early reductions in pain intensity or reduced opioid use within the first few hours), while many other trials show no sustained benefit in pain scores, opioid consumption, length of stay, or functional outcomes. Systematic reviews note small sample sizes, heterogeneous populations and methods, and inability to draw definitive conclusions about effectiveness or optimal delivery parameters.
Major safety concerns are documented: numerous case series, retrospective cohorts, and an FDA review identified an association between continuous intra-articular infusion of local anesthetics (including bupivacaine, lidocaine and others) and irreversible articular cartilage loss (chondrolysis) after arthroscopy. Device-related problems have also been reported, including elastomeric pump malfunctions that resulted in toxic serum ropivacaine levels and increased infection risk in some series.
| Study / Source | Key Finding |
|---|---|
| Singh et al (2005) | Reduced narcotic usage by ~50% and decreased pain scores at iliac crest harvest site (n=37) |
| Morgan et al (2006) | No difference in pain or narcotic use with 0.5% bupivacaine infusion at ICBG sites (n=60) |
| Reeves and Skinner (2009) | No benefit and possible increased pain/infection with intra-articular ropivacaine after TKA (no significant differences; higher pain/opioid in high-dose group) |
| Chen et al (2010) | No sustained pain relief with continuous intra-articular 0.5% bupivacaine after THA; lower VAS only at 0–2 hr, no difference in narcotic use or LOS (n=92) |
| Baulig et al (2011) | Study terminated early for toxic serum ropivacaine due to elastomeric pump malfunction; no difference in pain vs saline |
| Systematic reviews (Liu et al 2006; Zhang 2017) | Inconclusive evidence; heterogeneity and small trials limit conclusions; Zhang meta-analysis found small statistical pain reductions at 24–48 hr after TKA but likely not clinically significant and possible increased infection risk |
| FDA (2010) | Reviewed 35 reports of chondrolysis associated with continuous intra‑articular infusions of various local anesthetics; required label updates/warnings |
| Buchko et al (2015) | Retrospective cohort: 28.3% chondrolysis in exposure group after ACLR with intra‑articular bupivacaine+epinephrine vs 0% in controls; higher risk with 0.5% vs 0.25% (dose‑dependent signal) |
| Zhang et al (2017) meta-analysis | Local anesthetic infusion pumps associated with lower pain scores at 24 and 48 hr after TKA but likely not clinically significant; no LOS/DVT/PONV differences; possible increased infection |
| Ortega‑Garcia (2018) | Prospective cohort: trend to lower VAS at 48 hr with continuous levobupivacaine via elastomeric pumps after lumbar arthrodesis but not statistically significant for other metrics |
| Wu et al (2014) meta‑analysis | After open inguinal hernia repair, infusion pumps reduced pain Days 1–4 vs placebo; evidence small and low quality |
| Cottam et al (2007) | Small RCT in bariatric surgery: bupivacaine pump reduced opioid use post‑op vs PCA (n=40) |
| Bray et al (2007) | Abdominoplasty patients: pain pumps did not significantly improve pain management; pain scores numerically higher (non‑significant) |
| Sherwinter et al (2008) | On‑Q intraperitoneal bupivacaine reduced VAS through 48 hr after laparoscopic adjustable gastric banding vs saline (n=30) |
| Iyer et al (2010) | Ropivacaine infusion in bariatric surgery improved ambulation time but not pain, morphine requirement, or LOS |
| Cohen et al (2013) | Continuous intraperitoneal bupivacaine reduced morphine equivalents but not VAS or LOS in RYGBP retrospective review (n=289) |
| Medbery et al (2014) | CWIS in LRYGBP reduced narcotic and anti‑emetic use but did not improve pain control and slightly increased hospital costs |
| Ilfeld et al (2013) | Pilot crossover (n=3): prolonged ambulatory CPNB may resolve phantom limb pain in some patients; warrants larger RCT |
| Schwartzberg et al (2013) | Continuous subacromial bupivacaine infusion showed no detectable pain reduction after rotator cuff repair (n=88) |
| An et al (2020) systematic review | Subacromial analgesia after arthroscopic shoulder surgery: no clinically significant benefit; small OME reduction at 12 hr only; low‑to‑very‑low quality evidence |
| Diamantis et al (2021) | Elastomeric pumps enable outpatient prolonged antibiotic infusion but concerns about drug stability, degradation products, and need for close monitoring |
| Karimaghaei et al (2022) | OPAT eCIP cohort: 91 patients, 1,925 days; 93.4% cure rate, 6.6% side effects, notable ED visit/readmission rates and estimated substantial cost savings |
Experimental / Not Routinely Covered Indications
Coverage stance: mixed. While continuous infusion pumps have demonstrated limited or transient benefit in some studies, the overall evidence is inconsistent and safety concerns exist, so coverage is nuanced and may restrict certain uses or consider some applications experimental.
Specific experimental or limited-use areas highlighted include: continuous subcutaneous anti-emetic pumps in pregnancy (evidence limited to small uncontrolled series and one matched trial with tolerability issues and complications; recommended to remain experimental pending RCTs), prolonged ambulatory continuous peripheral nerve blocks (CPNB) for phantom limb pain (promising pilot data from a small crossover study suggesting possible durable benefit but requiring a large RCT), and intra-articular continuous local anesthetic infusions (associated with chondrolysis and therefore subject to safety cautions and utilization restrictions).
Experimental / Not Medically Necessary When
ALL of the following
- Continuous subcutaneous anti-emetic pumps in pregnancy (experimental): Continuous subcutaneous administration of metoclopramide or ondansetron for nausea and vomiting in pregnancy is considered experimental/limited due to very limited evidence (one matched controlled trial and case series), tolerability issues, notable complications, and need for RCTs; should be restricted to intractable cases unresponsive to standard therapy.
Reichmann & Kirkbride review and policy statement
- Prolonged ambulatory CPNB for phantom limb pain (experimental): Prolonged ambulatory continuous peripheral nerve block for phantom limb pain remains experimental/limited—evidence from a small pilot crossover study (Ilfeld pilot, n=3) suggests potential benefit but warrants large RCTs before routine use.
Pilot data only; further RCTs needed
- Intra-arterial/HAIP chemotherapy restricted: Hepatic arterial infusion pump (HAIP) chemotherapy for unresectable intrahepatic cholangiocarcinoma should be used only in clinical trials or at experienced centers in carefully selected cases (NCCN recommendation).
Policy lists HAIP as investigational/limited; NCCN guidance
- Elastomeric pumps for home IV antibiotics (limited/experimental per policy): Elastomeric pump use for home continuous IV antibiotic administration is listed as experimental/investigational in the policy (concerns about drug stability, degradation products, and need for monitoring), though some observational OPAT cohorts report favorable cure rates; use requires careful molecule-specific consideration and monitoring.
Policy flags elastomeric OPAT as investigational and cites stability/toxicity concerns
- Selected surgical indications considered experimental per policy: Infusion pumps for intra-lesional administration and intra-articular administration of narcotic analgesics/anesthetics and pumps for a range of specific procedures (arthroscopic shoulder surgery, bariatric surgery, cardiothoracic surgery, donor nephrectomy, free flap breast reconstruction, laparoscopic cholecystectomy, open inguinal hernia repair, total hip arthroplasty) are listed as experimental/ investigational in the policy due to insufficient evidence of effectiveness or safety.
Policy experimental list enumerates multiple surgical indications
Coding
Revision History
Policy effective date (Anesthetic and Antiemetic Infusion Pumps, Clinical Policy Bulletin #0607).
Last review of the policy (most recent review date listed).
Next scheduled review date for the policy.
OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.